Cel Sci Corporation (CVM)

[maverick1856]

I believe that these are the following issues facing CVM:

1- The market drove the price from over $10/share down to $0.50/share

2- Phase 3 progression stalled

3- the Company is cash deficient to reach the end of the phase 3 study

What needs to be done or is being done to resolve this

1- the market will need to see positive catalysts for the stock price to go higher, there is ~130M shares once fully diluted....if the float/fully diluted float was less these small runs would be magnified..

2- from the monthly enrollment data we are seeing phase 3 progression improvements, this item is/has been resolved

3- $$$...investors are waiting for visibility on how much $$ will need to be raised...once arbitration is settled this will be resolved..or at least visibility into the financing needs

Clearly from the Phase 2 studies, partnership deals the drug appears to be non-toxic which eliminates 60-75% of the phase 3 risk...and the phase 2 results support the primary endpoint being tested for in phase 2..granted this was on a minimal sample and not yet statistically significant to skip/fast track the phase 3..


Right now the stock will trade side-ways between $0.75 - $1.25 until arbitration is resolved, a step up in enrollment data might temporarily lift the stock price..but the big catalyst everyone is waiting for is arbitration and the clarity on how much more $$/dilution will need to be raised to get thru phase 3

If you are a betting individual (as most of us are to be in a 'penny' biotech with no approved product)...then you would load up prior to arbitration date...